NASDAQ:YMAB

Y-mAbs Therapeutics Stock Forecast, Price & News

$27.30
+0.51 (+1.90 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.56
Now: $27.30
$27.68
50-Day Range
$25.58
MA: $32.49
$37.12
52-Week Range
$24.77
Now: $27.30
$55.22
Volume267,118 shs
Average Volume300,085 shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Y-mAbs Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:YMAB
CUSIPN/A
CIKN/A
Phone646-885-8505
Employees125
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.01 per share

Profitability

Net Income$-81,030,000.00

Miscellaneous

Market Cap$1.19 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

Headlines

Y-mAbs Announces GPA33-SADA Data Presented at AACR
April 12, 2021 |  finance.yahoo.com
Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 2.7%
April 12, 2021 |  americanbankingnews.com
Oversold Conditions For Y-mAbs Therapeutics
March 24, 2021 |  nasdaq.com
YMAB Feb 2021 70.000 call
January 17, 2021 |  au.finance.yahoo.com
Y-mAbs Announces Sale of Priority Review Voucher
December 28, 2020 |  finance.yahoo.com
Y-mAbs Therapeutics: Further Upside After Approval
December 21, 2020 |  seekingalpha.com
See More Headlines

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

343rd out of 2,021 stocks

Pharmaceutical Preparations Industry

159th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$27.30
+0.51 (+1.90 %)
(As of 04/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive YMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Y-mAbs Therapeutics (NASDAQ:YMAB) Frequently Asked Questions

Is Y-mAbs Therapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Y-mAbs Therapeutics stock.
View analyst ratings for Y-mAbs Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Y-mAbs Therapeutics?

Wall Street analysts have given Y-mAbs Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Y-mAbs Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Y-mAbs Therapeutics?

Y-mAbs Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,620,000 shares, an increase of 27.9% from the March 15th total of 2,830,000 shares. Based on an average daily volume of 306,900 shares, the days-to-cover ratio is presently 11.8 days. Currently, 12.8% of the shares of the company are sold short.
View Y-mAbs Therapeutics' Short Interest
.

When is Y-mAbs Therapeutics' next earnings date?

Y-mAbs Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Y-mAbs Therapeutics
.

How were Y-mAbs Therapeutics' earnings last quarter?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) announced its quarterly earnings results on Friday, February, 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.84) by $0.36.
View Y-mAbs Therapeutics' earnings history
.

How has Y-mAbs Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Y-mAbs Therapeutics' stock was trading at $22.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, YMAB shares have increased by 18.8% and is now trading at $27.30.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for YMAB?

8 analysts have issued 1-year price targets for Y-mAbs Therapeutics' shares. Their forecasts range from $45.00 to $71.00. On average, they expect Y-mAbs Therapeutics' share price to reach $58.14 in the next year. This suggests a possible upside of 113.0% from the stock's current price.
View analysts' price targets for Y-mAbs Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Y-mAbs Therapeutics' key executives?

Y-mAbs Therapeutics' management team includes the following people:
  • Mr. Thomas Gad, Founder, Chairman, Pres & Head of Bus. Devel. and Strategy (Age 51, Pay $766.75k)
  • Dr. Claus Juan Møller San Pedro M.D., Ph.D., CEO & Director (Age 59, Pay $967.5k)
  • Mr. Bo Kruse, Exec. VP, Sec., Treasurer & CFO (Age 49, Pay $608.35k)
  • Mr. Joris Wiel Jan Wilms, Sr. VP & COO (Age 47)
  • Dr. Torben Lund-Hansen, Sr. VP & Head of Technical Operations (Age 70)
  • Dr. Steen Lisby M.D., M.Sc., Sr. VP & Chief Scientific Officer (Age 57)
  • Mr. Philip Herman, Sr. VP & Chief Commercial Officer (Age 42)
  • Dr. Vignesh Rajah, Sr. VP & Chief Medical Officer

Who are some of Y-mAbs Therapeutics' key competitors?

What other stocks do shareholders of Y-mAbs Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Corbus Pharmaceuticals (CRBP), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Vaxart (VXRT) and Amarin (AMRN).

When did Y-mAbs Therapeutics IPO?

(YMAB) raised $80 million in an IPO on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

What is Y-mAbs Therapeutics' stock symbol?

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Who are Y-mAbs Therapeutics' major shareholders?

Y-mAbs Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Pacer Advisors Inc. (0.00%). Company insiders that own Y-mAbs Therapeutics stock include Bo Kruse, David N Gill, James Healy, Johan Wedell-Wedellsborg, Mahiuddin Ahmed, Pedro Claus Juan Moller-San, Thomas Gad and Vignesh Rajah.
View institutional ownership trends for Y-mAbs Therapeutics
.

Which institutional investors are buying Y-mAbs Therapeutics stock?

YMAB stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include James Healy, Pedro Claus Juan Moller-San, and Vignesh Rajah.
View insider buying and selling activity for Y-mAbs Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Y-mAbs Therapeutics?

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Y-mAbs Therapeutics' stock price today?

One share of YMAB stock can currently be purchased for approximately $27.30.

How much money does Y-mAbs Therapeutics make?

Y-mAbs Therapeutics has a market capitalization of $1.19 billion. The company earns $-81,030,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis.

How many employees does Y-mAbs Therapeutics have?

Y-mAbs Therapeutics employs 125 workers across the globe.

What is Y-mAbs Therapeutics' official website?

The official website for Y-mAbs Therapeutics is www.ymabs.com.

Where are Y-mAbs Therapeutics' headquarters?

Y-mAbs Therapeutics is headquartered at 230 Park Avenue Suite 3350, NEW YORK NY, 10169.

How can I contact Y-mAbs Therapeutics?

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.